BMB Reports 2017; 50(3): 138-143  
Neuropeptide Y-based recombinant peptides ameliorate bone loss in mice by regulating hematopoietic stem/progenitor cell mobilization
Min Hee Park1,2,3, Namoh Kim1,2,3, Hee Kyung Jin1,4,* & Jae-sung Bae1,2,3,*
1Stem Cell Neuroplasticity Research Group, Kyungpook National University, Daegu 41566, 2Department of Physiology, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu 41944, 3Department of Biomedical Science, BK21 Plus KNU Biomedical Convergence Program, Kyungpook National University, Daegu 41944, 4Department of Laboratory Animal Medicine, College of Veterinary Medicine, Kyungpook National University, Daegu 41566, Korea
Correspondence to: Jae-sung Bae, Tel: +82-53-420-4815; Fax: +82-53-424-3349; E-mail:, Hee Kyung Jin, Tel: +82-53-950-5966; Fax: +82-53-950-5955; E-mail:
Received: November 15, 2016; Published online: March 31, 2017.
© Korean Society for Biochemistry and Molecular Biology. All rights reserved.

Ovariectomy-induced bone loss is related to an increased deposition of osteoclasts on bone surfaces. We reported that the 36-amino-acid-long neuropeptide Y (NPY) could mobilize hematopoietic stem/progenitor cells (HSPCs) from the bone marrow to the peripheral blood by regulating HSPC maintenance factors and that mobilization of HSPCs ameliorated low bone density in an ovariectomy-induced osteoporosis mouse model by reducing the number of osteoclasts. Here, we demonstrated that new NPY peptides, recombined from the cleavage of the full-length NPY, showed better functionality for HSPC mobilization than the full-length peptide. These recombinant peptides mediated HSPC mobilization with greater efficiency by decreasing HSPC maintenance factors. Furthermore, treatment with these peptides reduced the number of osteoclasts and relieved ovariectomy-induced bone loss in mice more effectively than treatment with full-length NPY. Therefore, these results suggest that peptides recombined from full-length NPY can be used to treat osteoporosis.
Keywords: Bone loss, Hematopoietic stem/progenitor cell, Mobilization, Neuropeptide Y-based recombinant peptides, Osteoclasts

This Article